Galina Ryltseva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Galina Ryltseva has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Aleksei Dorokhin
Siberian Federal University, 79 Svobodny pr., Krasnoyarsk 660041, Russia
3 shared publications - Sergei Y. Lipaikin
Siberian Federal University, 79 Svobodny pr., Krasnoyarsk 660041, Russia
3 shared publications - Tatiana Grigorievna Volova
Siberian Federal University, 79 Svobodny pr., Krasnoyarsk 660041, Russia and Institute of Biophysics SB RAS, Federal Research Center “Krasnoyarsk Science Center SB RAS”, 50/50 Akademgorodok, Krasnoyarsk 660036, Russia
3 shared publications - Alexander V. Shabanov
Kirensky Institute of Physics, Federal Research Center Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences, Krasnoyarsk 660036, Russia
2 shared publications - Ekaterina Igorevna Shishatskaya
Siberian Federal University, 79 Svobodny pr., Krasnoyarsk 660041, Russia
2 shared publications Alexey E. Dudaev
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 14
5-fluorouracil-loaded polyhydroxyalkanoate micro- and nanoparticles: preparation, characterisation and in vitro evaluation
Background and purpose: 5‑fluorouracil (5‑FU) is a widely used antimetabolite chemotherapeutic agent. However, it has substantial cytotoxicity and may cause serious adverse effects, including gastrointestinal toxicity, myelosuppression, and, less commonly, cardiac and neurologic toxicity. To achieve sustained release and reduce systemic exposure and administration frequency, 5-FU can be microencapsulated in biodegradable, non-toxic polyhydroxyalkanoate matrices. Experimental approach: In this research, 5-FU-loaded poly(3-hydroxybutyrate) (P3HB) and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (P3HBV) micro- and nanoparticles were prepared via spray drying and single emulsion solvent evaporation methods. The obtained particles were characterized in terms of their average hydrodynamic size, zeta potential, surface morphology, drug loading, encapsulation efficiency, release patterns, hemolytic activity, and cytotoxicity to HeLa cervical cancer cells. Key results: The obtained 5-FU-loaded micro- and nanoparticles had a regular spherical shape without surface defects. The nanoparticles were nearly identical in size regardless of the presence of 5‑FU. In contrast, the encapsulation of 5‑FU into microparticles by spray drying caused measurable increases in particle size, with the average hydrodynamic diameter increasing by 21.0 % for P3HB and by 28.6 % for P3HBV. Although the single emulsion solvent evaporation technique did not achieve therapeutically relevant 5‑FU loading, spray-dried microparticles showed satisfactory drug loading and sustained release of 5-FU over 48 h. The microparticles exhibited pronounced cytotoxicity against HeLa cervical cancer cells while demonstrating lower hemolytic activity than free 5‑FU. Conclusion: In this study, the promising drug-loaded systems based on polyhydroxyalkanoate microparticles were prepared and characterized for sustained 5-FU delivery in the therapy of cervical cancer.
- 13 October 2026
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 14
Open Access5-fluorouracil-loaded polyhydroxyalkanoate micro- and nanoparticles: preparation, characterisation and in vitro evaluation
Background and purpose: 5‑fluorouracil (5‑FU) is a widely used antimetabolite chemotherapeutic agent. However, it has substantial cytotoxicity and may cause serious adverse effects, including gastrointestinal toxicity, myelosuppression, and, less commonly, cardiac and neurologic toxicity. To achieve sustained release and reduce systemic exposure and administration frequency, 5-FU can be microencapsulated in biodegradable, non-toxic polyhydroxyalkanoate matrices. Experimental approach: In this research, 5-FU-loaded poly(3-hydroxybutyrate) (P3HB) and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (P3HBV) micro- and nanoparticles were prepared via spray drying and single emulsion solvent evaporation methods. The obtained particles were characterized in terms of their average hydrodynamic size, zeta potential, surface morphology, drug loading, encapsulation efficiency, release patterns, hemolytic activity, and cytotoxicity to HeLa cervical cancer cells. Key results: The obtained 5-FU-loaded micro- and nanoparticles had a regular spherical shape without surface defects. The nanoparticles were nearly identical in size regardless of the presence of 5‑FU. In contrast, the encapsulation of 5‑FU into microparticles by spray drying caused measurable increases in particle size, with the average hydrodynamic diameter increasing by 21.0 % for P3HB and by 28.6 % for P3HBV. Although the single emulsion solvent evaporation technique did not achieve therapeutically relevant 5‑FU loading, spray-dried microparticles showed satisfactory drug loading and sustained release of 5-FU over 48 h. The microparticles exhibited pronounced cytotoxicity against HeLa cervical cancer cells while demonstrating lower hemolytic activity than free 5‑FU. Conclusion: In this study, the promising drug-loaded systems based on polyhydroxyalkanoate microparticles were prepared and characterized for sustained 5-FU delivery in the therapy of cervical cancer.
- Open Access
- 4 June 2025
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 13 (3) , 2723
Effect of surfactants and polymer composition on the characteristics of polyhydroxyalkanoate nanoparticles
Background and purpose: Polyhydroxyalkanoates (PHAs) are biodegradable polyesters of bacterial origin that are actively studied as matrices for the preparation of nanoparticulate drug delivery systems. The most significant parameters affecting PHAs nanoparticles (NPs) characteristics are polymer composition and the type of surfactant used to stabilize the emulsion during NPs preparation. However, there are only a few studies in the literature investigating the effect of these factors on the characteristics of PHA NPs. Experimental approach: Blank poly(3-hydroxybutyrate) (P3HB) and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (P3HBV) NPs were produced and characterized in terms of their size, morphology and zeta potential. Poly(vinyl alcohol) (PVA) with various molecular weights (31-50 and 85-124 kDa), as well as Tween 20 (TW20), Tween 80 (TW80), sodium deoxycholate (SDC) and sodium dodecyl sulphate (SDS) were used as surfactants. For NPs that formed stable aqueous suspensions and had the most desirable characteristics (P3HB/PVA31-50 and P3HBV/PVA31-50), hemolytic activity and cytotoxicity to HeLa and C2C12 cells in vitro were determined. Key results: NPs of both P3HB and P3HBV obtained using PVA with the Mw of 31-50 kDa as a surfactant had regular spherical shape, uniform size distribution, average diameter of about 900 nm and zeta potential of -28.5 and -28.7 mV, respectively. PVA85-124, TW20 and TW80, as well as SDC and SDS as surfactants, did not show satisfactory results due to suspension gelation, formation of hollow NPs with irregular shape and poor resuspension after washing and freeze-drying, respectively. P3HB/PVA31-50 and P3HBV/PVA31-50 NPs did not have hemolytic activity and did not show pronounced cytotoxicity to HeLa and C2C12 cells in the concentration range from 10 to 500 μg mL-1, so these samples were regarded as safe and biocompatible. Conclusion: In this study, the effect of various non-ionic and anionic surfactants on the characteristics of P3HB and P3HBV NPs was investigated. PVA31-50 was found to be effective in producing NPs of both studied polymers with good biocompatibility and favorable characteristics, making them suitable for drug delivery applications. In contrast, other studied surfactants, i.e., PVA85-124, TW20, TW80, SDC and SDS, require further investigation. The obtained findings may promote the development of novel PHA-based nanomedicines.
- 4 June 2025
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 13 (3) , 2723
Open AccessEffect of surfactants and polymer composition on the characteristics of polyhydroxyalkanoate nanoparticles
Background and purpose: Polyhydroxyalkanoates (PHAs) are biodegradable polyesters of bacterial origin that are actively studied as matrices for the preparation of nanoparticulate drug delivery systems. The most significant parameters affecting PHAs nanoparticles (NPs) characteristics are polymer composition and the type of surfactant used to stabilize the emulsion during NPs preparation. However, there are only a few studies in the literature investigating the effect of these factors on the characteristics of PHA NPs. Experimental approach: Blank poly(3-hydroxybutyrate) (P3HB) and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (P3HBV) NPs were produced and characterized in terms of their size, morphology and zeta potential. Poly(vinyl alcohol) (PVA) with various molecular weights (31-50 and 85-124 kDa), as well as Tween 20 (TW20), Tween 80 (TW80), sodium deoxycholate (SDC) and sodium dodecyl sulphate (SDS) were used as surfactants. For NPs that formed stable aqueous suspensions and had the most desirable characteristics (P3HB/PVA31-50 and P3HBV/PVA31-50), hemolytic activity and cytotoxicity to HeLa and C2C12 cells in vitro were determined. Key results: NPs of both P3HB and P3HBV obtained using PVA with the Mw of 31-50 kDa as a surfactant had regular spherical shape, uniform size distribution, average diameter of about 900 nm and zeta potential of -28.5 and -28.7 mV, respectively. PVA85-124, TW20 and TW80, as well as SDC and SDS as surfactants, did not show satisfactory results due to suspension gelation, formation of hollow NPs with irregular shape and poor resuspension after washing and freeze-drying, respectively. P3HB/PVA31-50 and P3HBV/PVA31-50 NPs did not have hemolytic activity and did not show pronounced cytotoxicity to HeLa and C2C12 cells in the concentration range from 10 to 500 μg mL-1, so these samples were regarded as safe and biocompatible. Conclusion: In this study, the effect of various non-ionic and anionic surfactants on the characteristics of P3HB and P3HBV NPs was investigated. PVA31-50 was found to be effective in producing NPs of both studied polymers with good biocompatibility and favorable characteristics, making them suitable for drug delivery applications. In contrast, other studied surfactants, i.e., PVA85-124, TW20, TW80, SDC and SDS, require further investigation. The obtained findings may promote the development of novel PHA-based nanomedicines.
- Open Access
- 9 October 2024
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 12 (6) , 925-942
Spray-dried cyclophosphamide-loaded polyhydroxyalkanoate microparticles: design and characterization
Background and purpose: Cyclophosphamide (CP) is a widely used antitumor and immunosuppressive drug, but it is highly cytotoxic and has carcinogenic and teratogenic potential. To reduce adverse effects of CP therapy and the frequency of its administration, the microencapsulation of CP into biodegradable polymeric matrices can be performed. However, according to the literature, only a few polymers were found suitable to encapsulate CP and achieve its’ sustained release. Experimental approach: In this research, spray-dried cyclophosphamide-loaded poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) microparticles were prepared and characterized in terms of their average hydrodynamic diameter, polydispersity index, surface morphology, zeta potential, encapsulation efficiency, drug loading, thermal properties and cytotoxicity against 3T3 cells. Key results: The obtained CP-loaded microparticles had a regular spherical shape, uniform size distribution with an average diameter of 4.21±0.04 μm and zeta potential of -34.2±0.2 mV. The encapsulation of cyclophosphamide into the PHBV matrix led to a decrease in melting and degradation temperatures and an increase in diameter, glass transition and cold crystallization temperatures compared to blank microparticles. Moreover, microencapsulation of cyclophosphamide lowered its cytotoxicity compared to the pure drug: the number of dead cells in the culture decreased by 28 %, while their metabolic activity increased by 20 %. The cumulative in vitro drug release studies showed a gradual release of CP up to 18 days, so the obtained microparticle formulation can be used as a sustained-release cyclophosphamide delivery system. Conclusion: In this research, a novel cyclophosphamide-loaded platform based on PHBV microparticles was established and characterized. Overall, this study offers promising prospects for cancer therapy in the future.
- 9 October 2024
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 12 (6) , 925-942
Open AccessSpray-dried cyclophosphamide-loaded polyhydroxyalkanoate microparticles: design and characterization
Background and purpose: Cyclophosphamide (CP) is a widely used antitumor and immunosuppressive drug, but it is highly cytotoxic and has carcinogenic and teratogenic potential. To reduce adverse effects of CP therapy and the frequency of its administration, the microencapsulation of CP into biodegradable polymeric matrices can be performed. However, according to the literature, only a few polymers were found suitable to encapsulate CP and achieve its’ sustained release. Experimental approach: In this research, spray-dried cyclophosphamide-loaded poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) microparticles were prepared and characterized in terms of their average hydrodynamic diameter, polydispersity index, surface morphology, zeta potential, encapsulation efficiency, drug loading, thermal properties and cytotoxicity against 3T3 cells. Key results: The obtained CP-loaded microparticles had a regular spherical shape, uniform size distribution with an average diameter of 4.21±0.04 μm and zeta potential of -34.2±0.2 mV. The encapsulation of cyclophosphamide into the PHBV matrix led to a decrease in melting and degradation temperatures and an increase in diameter, glass transition and cold crystallization temperatures compared to blank microparticles. Moreover, microencapsulation of cyclophosphamide lowered its cytotoxicity compared to the pure drug: the number of dead cells in the culture decreased by 28 %, while their metabolic activity increased by 20 %. The cumulative in vitro drug release studies showed a gradual release of CP up to 18 days, so the obtained microparticle formulation can be used as a sustained-release cyclophosphamide delivery system. Conclusion: In this research, a novel cyclophosphamide-loaded platform based on PHBV microparticles was established and characterized. Overall, this study offers promising prospects for cancer therapy in the future.